In AL-MM and AL-PCMM, the survival time was significantly shorter in patients with an ALP ≥ 187.5 IU/L (Fig. 1A; median survival time of 1.0 vs. 32.0 months; P<0.001), GGT ≥ 85 IU/L (Fig. 1B; median survival time of 4.0 vs. 30.0 months; P=0.008), TBIL ≥20 μmol/L (Fig. 1C; median survival time of 1.0 vs. 30.0 months; P=0.010), CTNI ≥ 0.1 ng/mL (Fig. 1D; median survival time of 1.0 vs. 30.0 months; P=0.010), EF < 50% (Fig. 1E; median survival time of 7.0 vs. 30.0 months; P=0.015), and BU staging system stage ≥ III (Fig. 1F; median survival time of 1.0 vs. 30.0 months; P=0.002). Here, TNNI3 is linked to Miyoshi myopathy.